Iraqi Registry Data Proves Safety and Efficacy of Switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis

الملخص

Background: Adalimumab is approved for Rheumatoid Arthritis (RA). In 2021, A biosimilar (ABP501; Amgevita®) was licensed in Iraq. The current study aimed to ensure the safety and Efficacy of Amgevita-Adalimumab biosimilar- in RA Patients in Iraq. Subjects and Methods: A Prospective Observational Study Started on 69 RA Records Receiving Amgevita. Data collected from the local registry was then examined for disease activity and adverse reactions for 9 months follow-up. Results: Thirty patients completed the 9 months of the study: aged (49±14) years; 77.5% females. After 3, 6, and 9 months of follow-up, patients' mean ± (SD) Clinical Disease Activity Index (CDAI) was 27.8 (13.60) which was statistically lower (19.80) (6.96), 17.70 (2.790), and 19 (1.040), p